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T
he mechanisms that ligands 
use to send signals into cells 
vary among cell types and cell 
functions. For example, estrogen 
receptors (ERs) are critical regulators 
of the reproductive system, the central 
nervous system, and bone metabolism. 
There are two known members of 
the ER family (Keen and Davidson 
2003). The natural ligand for the ER 
is estradiol, although thousands of 
different molecules have been screened 
for altered signals through the ERs. 
The odorant family of receptors (ORs) 
also detects a large array of ligands. 
Thousands of odorous molecules 
of different sizes and shapes can be 
discriminated. In contrast to the ER, 
in humans this task is accomplished 
by the 350 ORs (there are 906 OR 
genes, including the pseudogenes 
and degenerate genes [Glusman et 
al. 2001]). Rodents express at least 3-
fold more ORs than humans, perhaps 
due to their increased reliance on 
distinguishing odors (Young and Trask 
2002). The ORs are an example in 
which there is large diversity in ligands 
and in the cognate receptors.
The key responsibilities of T cells 
of the immune system are controlling 
pathogens and orchestrating the 
function of other cells in the immune 
system. For example, virally infected 
cells display viral proteins on their cell 
surface that can be recognized by T 
cell receptors (TCRs). If there were 
only two TCRs, like the ERs, or even 
350 TCRs, like the ORs, then how 
would the T cells distinguish what is a 
viral protein versus a cellular protein, 
and how would immunity develop to 
a virus that was not recognized by one 
of those TCRs? To solve this problem, 
the TCR family has evolved so that it 
can hypothetically recognize an infinite 
number of such proteins. 
TCR Diversity
Most T cells express many copies of 
one TCR selected during development 
of the T cell. The TCR consists of two 
different proteins, the  and  chains. 
The  chain is composed of genetic 
segments from three families: 42 V, 
61 J (five pseudogenes), and one C 
segment. The  chain is composed 
of four segments: 47 V, two D, 13 
J, and one C segment (Arden et al. 
1995; NCBI 2003). Connection of 
all permutations of these different 
DNA segments during development 
by a mechanism known as somatic 
recombination can produce 
approximately 3 million different 
TCRs. (This mechanism is also used 
by B cell receptors, by transposons, 
and in chromosomal translocations 
in tumors.) Additional diversity is 
introduced to the repertoire of T 
cells by the molecular joining of the 
segments. This junctional diversity 
results from the addition of random 
numbers of basepairs between the V 
and J segments in the  chain as well 
as between the V, D, and J segments in 
the  chain (Roth 2003). According 
to one estimate, the total number of 
different TCRs that can be formed 
with this process is approximately 1018 
(Janeway et al. 1999)! 
However, we have around 1014 total 
cells, and only approximately 1011 
of these are T cells. Therefore, it is 
impossible for all TCRs to be present 
in one person. Many T cells are deleted 
in the process of T cell development. 
This process of negative selection 
greatly reduces the number of TCRs 
that recognize self-proteins; 95%–98% 
of all T cells are deleted. During 
development, T cells are also positively 
selected, and only those with TCRs 
that can react with the ligand survive 
(Palmer 2003).
TCR Ligand
The molecular ligand recognized 
by the TCR is unique. Unlike the ERs 
and ORs that recognize molecules in 
solution, TCRs recognize a cell-bound 
complex that includes a protein known 
as an MHC (major histocompatibility 
complex) molecule and a short peptide 
of less than 20 amino acids (Margulies 
1999) (Figure 1). These complexed 
ligands, or antigens, are on the surface 
of nearly all healthy cells. MHC class 
I predominantly binds peptides from 
inside the cell. These peptides can 
be derived from viruses, which are 
recognized by T cells as foreign. The 
consequence of this recognition is 
destruction of the infected cells by the 
T cells. Bacteria or cell debris brought 
into the cell from outside is degraded 
and the peptides bind to MHC class 
II molecules. The function of the T 
cells that recognize these antigens is 
different from those that bind MHC 
class I. These T cells typically respond 
by producing cytokines, proteins that 
bind to receptors on other cells that 
augment immunity. The MHC class 
I– and class II–bound peptides also 
include fragments of self-proteins. Most 
of the T cells specific for these peptides 
are deleted during development. The T 
cells that are not deleted are controlled 
by other mechanisms so that these T 
cells do not kill healthy cells resulting 
in autoimmunity.
Multimers
For modulation of the T cell 
response, characterizing the 
responding T cell repertoire is 
essential. A complexity of this goal is 
that many genetically distinct T cells 
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may recognize one antigen and one 
T cell may recognize many antigens. 
This redundancy results in low 
affinity of the TCR for peptide–MHC 
(the average KD for TCR binding to 
peptide–MHC class I in solution is 10 
µM [Davis et al. 1998]). Direct labeling 
and/or quantification of antigen-
specific T cells using the peptide–MHC 
ligand is hindered by this low affinity. 
Although T cells in the blood are easily 
detectable (1,000–2,000 cells/µl), 
analysis of the low-frequency, antigen-
specific T cells is difficult. At its peak, a 
T cell response to a strong viral antigen 
may constitute 5% of the T cells in 
the blood and a T cell response to a 
tumor may be undetectable without 
amplification of the response in vitro. 
Until recently, methods for identifying 
T cells responding to an antigen 
required growth in vitro or analysis 
of T cells that included many antigen 
specificities. These methods are fraught 
with disadvantages since not all of the 
T cells with the same antigen specificity 
will proliferate and survive equally. 
However, the problem of the weak 
affinity and low frequency of the 
responding T cells has been solved 
by the introduction of “multimer” 
technology (Klenerman et al. 2002). 
Molecules referred to as tetramers 
(Altman et al. 1996) or dimers (Greten 
et al. 1998) that contain multiple 
copies of peptide–MHCs bind to more 
than one TCR on a T cell at one time, 
resulting in increased avidity. Thus, 
when one TCR lets go of a peptide–
MHC molecule due to weak affinity, 
the multimer likely stays bound to the 
T cells because another peptide–MHC 
is still complexed with a different TCR 
on the same T cell. If the multimer 
is labeled with a fluorochrome, then 
the specific cells can be resolved 
from the population and analyzed. 
Current protocols detect specific T cell 
populations as small as 0.1%.
Peptide–MHC Microarrays
Analyzing T cells with individual 
multimers provides prudent 
information for some analyses. 
In addition, the parameters used 
for characterization of T cells 
are blossoming as the molecular 
understanding of T cells expands. 
Another complexity is that not all 
people respond to the same antigens 
even if the same MHCs are expressed. 
Finally, the number of T cells in a 
sample is not always sufficient to 
perform the necessary assays. For 
example, many fewer T cells can 
be isolated from tumors or lesions 
relative to what can be isolated from 
blood. Soen et al. (2003) chose to 
address these problems by developing 
a new technique, which combines the 
specificity and sensitivity of multimers 
with microarray technology. Microarray 
technology, originally developed to 
compare gene expression profiles, 
works on the general premise that a 
large numbers of ligands or substrates 
are attached in an ordered array to a 
surface (Gibson 2003). The molecular 
partner, or, in this case, T cells bearing 
potential cognate TCR, is passed over 
the array in solution phase. Binding 
results in a detectable signal. The key 
to the efficiency of this technique is 
that the array requires small amounts 
of the molecular partner, or T cells, 
to be used to screen for the reciprocal 
molecule.
In this new technology, glass slides 
are spotted with peptide–MHC 
multimers and antibodies that bind 
to specific determinants on T cells. 
Since the ligand is immobilized, high 
concentrations of peptide–MHC 
monomer might achieve the same 
goal as the multimers. In the examples 
illustrated in the paper by Soen et al. 
(2003), TCR specificity for the peptide–
MHC is demonstrated by screening 
spots that contain different peptides 
and MHC molecules with T cells from 
transgenic and vaccinated mice. Such 
arrays could potentially have thousands 
of spots that could lead to a detailed 
characterization of a T cell population 
from a sample as small as 100 µl. 
Thus, high-throughput detection and 
characterization of rare populations of 
antigen-specific T cells may be achieved 
using small sample volumes.
Example of Using Peptide–MHC 
Microarrays: Characterization of T 
Cell Responses to a Cancer Vaccine 
One promising method of 
augmenting the T cell response to 
tumors is by vaccinating patients with 
peptides that have small alterations 
in their amino acid sequence relative 
to the peptides that are present on 
the surface of the tumor cells. When 
bound to MHC, these “mimotopes” 
activate T cells that may cross-react 
with the peptide–MHC expressed on 
the tumor. Currently, about 10%–20% 
of melanoma patients given vaccines 
that include these mimotopes have 
a clinical response to their tumors 
(Parmiani et al. 2002). The efficacy of 
these treatments needs to be improved. 
DOI: 10.1371/journal/pbio.0000078.g001
Figure 1. MHC Class I and MHC Class II Bind to Specific TCRs
MHC class I and MHC class II bind to specific TCRs on the surface of the MHC molecule 
that is facing you. The peptide is presented by the MHC to the TCR like a hotdog in 
a bun; the peptide typically constitutes approximately 15% and the MHC molecule 
constitutes approximately 85% of the surface that the TCR binds. (A) shows a molecular 
structure of the human MHC class I, HLA-A2, bound to a tumor antigen, MAGE-4 
(Hillig et al. 2001). This structure is distinct from (B), which shows the human MHC 
class II molecule HLA-DR1 bound to a peptide derived from the Epstein–Barr virus 
gp42 protein (Mullen et al. 2002) in three ways. (1) The MHC class I peptide is shorter 
(average of nine amino acids versus 15 amino acids). (2) The ends of the peptide-
binding grooves are closed in the MHC class I. (3) Although it is not evident in the 
structures shown, the binding groove from MHC class II is produced from two distinct 
molecules; the groove from MHC class I forms from one protein. The class I and II 
molecules can be found in animals from jawed vertebrates on up the evolutionary tree. 
(Figure produced with Cn3D version 4 from the National Center for Biotechnology 
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This increase could be accomplished 
by improving the mimotope or the 
responding T cells. Which T cells to 
specifically target with the vaccine 
and what is required to activate those 
T cells could be determined using 
the peptide–MHC and antibody 
microarrays. The ability of tumor-
derived T cells to bind to a panel 
of mimotope–MHC complexes and 
the corresponding tumor-associated 
antigens would indicate whether the 
patients had T cells to react with the 
mimotope or whether these T cells 
were deleted during development. 
With a simple, economical method to 
screen the available T cell repertoire 
to tumor antigens and mimotopes, 
individual treatments could be easily 
formulated and clinical response to 
tumors could be improved.
In addition to cancer, the peptide–
MHC microarray technology could 
also improve the analysis of the T cells 
responding to infectious diseases, 
autoimmune diseases, and transplants. 
A more advanced understanding of the 
available T cells will be beneficial for 
each of these conditions. 
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